Solid Tumor Testing Market in the US CAGR Growth of 11.1% by 2020 - Trends, Technologies & Opportunities Report 2016-2020 - Key Vendors: Roche Diagnostics, 20/20 GeneSystems, Adaptive Biotechnologies

DUBLIN, March 4, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/t5czwt/solid_tumor) has announced the addition of the "Solid Tumor Testing Market in the US 2016-2020" report to their offering.

This comprehensive report predicts that the solid tumor testing market in the US will grow with a CAGR of 11.1% during the 2016-2020 period.

Commenting on the report, an analyst from the research team said: Ready-to-use reagents offer many advantages such as avoiding calculation, dilution, infection, and pipetting errors; and also save time. The focus on disease treatment and gaining accurate results through sample analysis will boost the consumption of ready-to-use reagents during the forecast period.

According to the report, Proteins and genes control various functions of the body. Any defect in a particular protein or gene structure will result in the occurrence of specific disorders. The development of personalized drugs depends on the identification and study of protein and gene expressions. These personalized medicines are regulated and labeled along with a specific diagnostic test, referred to as companion diagnostic.

Questions Answered:

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the strengths and weaknesses of the key vendors?

Companies Mentioned:

• Abbott Molecular
• Agilent Technologies (Dako)
• Beckman Coulter
• Roche Diagnostics
• 20/20 GeneSystems
• Adaptive Biotechnologies
• Advanced Cell Diagnostics
• Affymetrix
• Agena Bioscience
• Ambry Genetics
• ApoCell
• Avant Diagnostics
• Biological Dynamics
• Bodit

Report Structure:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Healthcare reform in US

PART 06: Reimbursement and coverage: An overview

PART 07: Market landscape

PART 08: Market segmentation by technology

PART 09: Market segmentation by cancer type

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

PART 16: Appendix

PART 17: About Author

For more information visit http://www.researchandmarkets.com/research/t5czwt/solid_tumor

Media Contact:

Research and Markets

Laura Wood, Senior Manager

[e-mail]

For E.S.T Office Hours Call [phone]

For U.S./CAN Toll Free Call [phone]

For GMT Office Hours Call [phone]

U.S. Fax: [phone]

Fax (outside U.S.): [phone]